Multiple Myeloma
Conference Coverage
SC daratumumab deemed feasible for every multiple myeloma patient
CHICAGO – In the COLUMBA trial, subcutaneous daratumumab proved noninferior to intravenous daratumumab in overall response rate and maximum trough...
Latest News
FDA approves Xpovio for relapsed/refractory multiple myeloma
The oral therapy was approved for patients who have received at least four prior therapies and whose disease is resistant to several other forms...
News
Daratumumab regimen shows benefit in transplant-ineligible myeloma
The alkylator-free regimen of daratumumab plus lenalidomide and dexamethasone appears safe and effective for patients who are ineligible for stem...
Conference Coverage
Lenalidomide may reduce risk of progression from SMM to MM
At 3 years, the rate of progression-free survival was 91% in patients with smoldering multiple myeloma who were randomized to lenalidomide and 66...
News
CAR T-cell therapy bb2121 performs well in phase 1 trial of refractory multiple myeloma
The objective response rate of 85% among 33 heavily pretreated patients suggests “promising efficacy.”
News
ASCO, CCO issue multiple myeloma treatment guidelines
An expert panel convened by ASCO and Cancer Care Ontario reviewed 124 recent studies to develop nearly 50 specific recommendations in transplant-...
News
FDA halts enrollment in trial of venetoclax for multiple myeloma
Increased risk of fatal infections
News
Oral triplet deemed effective in relapsed/refractory myeloma
Combination clarithromycin, pomalidomide, and dexamethasone may be a treatment option for patients with relapsed or refractory multiple myeloma....
News
Myeloma risk score has treatment-planning potential
The score could be used to modify doses prior to treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
